6/28/23, 12:08 AM CHLAZIDOXY Pathway Feedback Search Clinical Topics Home Studies CHLAZIDOXY CHLAZIDOXY Disease Chlamydia trachomatis infection Trial question Is doxycycline superior to azithromycin in women with concurrent anorectal and vaginal Chlamydia trachomatis infection? Study design Multi-center Open label RCT Population 357 female patients Inclusion criteria: adult women positive for anorectal and vaginal Chlamydia trachomatis infection Key exclusion criteria: symptoms suggestive of pelvic inflammatory disease; receipt of antibiotic with antichlamydial activity within 21 days of screening; breast-feeding; severe liver or cardiac disease Interventions N=184 doxycycline (100 mg twice per day for 7 days) N=173 azithromycin (a single 1 g dose) Primary outcome Microbiological anorectal cure 94.0 % 94 85 70.5 % 47.0 % Significant increase 23.5 % NNH = 11 0.0 % Doxycycline Azithromycin https://web.pathway.md/studies/recCueJfPxDdoFEMd 1/2 6/28/23, 12:08 AM CHLAZIDOXY Pathway Significant increase in microbiological anorectal cure (94% vs. 85%; OR 2.33, 95% CI 1.1 to 4.76) Safety outcomes No significant difference in adverse events including gastrointestinal disorders; serious adverse effects. Conclusion In adult women positive for anorectal and vaginal Chlamydia trachomatis infection, doxycycline was superior to azithromycin with respect to microbiological anorectal cure. Reference Olivia Peuchant, Edouard Lhomme, Pervenche Martinet et al. Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2022 May 9;S1473-3099(22)00148-7. Open reference URL https://web.pathway.md/studies/recCueJfPxDdoFEMd 2/2